This underscores the clinical imperative to identify prognostic biomarkers differentiating highly immunogenic "hot tumors" from less responsive "cold ones." In the current study, LOXL1 was identified as a novel potential predictor for the prognosis and immunotherapy response of CRC patients using WGCNA based on public transcriptomic datasets. This evidence concerns the gene LOXL1 and colorectal carcinoma.